Year: 2025

WILMINGTON, Del., Nov. 06, 2025 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for backup generators, gas pipelines and other critical infrastructure assets, announced results for its three and nine months ended September 30, 2025 (Q3’25 and 9M’25). Acorn will hold an investor call today at 11 a.m. ET (details below).Summary Financial Results ($ in thousands) Q3’25 Q3’24 Change   9M’25 9M’24 ChangeMonitoring revenue $ 1,560   $ 1,138   +37.1 %   $ 4,149   $ 3,350   +23.9 %Hardware revenue $ 918   $ 1,912   -52.0 %   $ 4,952   $ 4,107   +20.6 %Total revenue(1) $ 2,478   $ 3,050   -18.8 %   $ 9,101   $ 7,457   +22.0 %Gross margin   78.5 %   71.7 % +680bps     75.9 %   73.0 % +290bpsNet income to stockholders $ 252   $ 725   -65.2 %   $ 1,436   $ 1,061   +35.3 %Net...

Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial HighlightsTotal net revenue of $67.5 million MACI® net revenue growth of 25% to $55.7 million Burn Care net revenue of $11.8 million, consisting of $10.4 million of Epicel® revenue and $1.5 million of NexoBrid® revenue Gross...

ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025; expected to be sufficient to fund operations into Q4 of 2027CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. “We are looking forward to sharing a clinical update later this quarter from our silevertinib Phase 2 trial in newly diagnosed patients with EGFRm NSCLC,” said Mark Velleca, M.D., Ph.D.,...

– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3’25 with Cash, Cash Equivalents and Marketable Securities of $285.9 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter ended September 30, 2025, and provided...

LOWELL, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal fourth quarter and fiscal year ended October 3, 2025. Fourth Quarter Fiscal Year 2025 GAAP ResultsRevenue was $261.2 million, an increase of 30.1%, compared to $200.7 million in the previous year fiscal fourth quarter and an increase of 3.6% compared to $252.1 million in the prior fiscal quarter; Gross margin was 54.5%, compared to 54.7% in the previous year fiscal fourth quarter and 55.3% in the prior fiscal quarter; Income from operations was $39.6 million, or 15.2% of revenue, compared to income from operations of $27.5 million, or 13.7% of revenue, in the previous year fiscal fourth quarter and income from operations...

– $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) – – Aligned with U.S. FDA on Registrational Path for Zervimesine – – Expanded Access Program for Dementia with Lewy Bodies Ongoing – PURCHASE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “The $30 million registered direct offering enables us to begin preparations for the next stage of development for zervimesine (CT1812),” stated Lisa Ricciardi, Cognition’s president and CEO. “The alignment we achieved with the FDA on a registrational...

Solo Brands Accelerates Structural Cost Reduction to Match Current Demand Levels; Delivers $11 Million of Operating Cash in Q3, Marking Second Consecutive Quarter of Positive Cash Flow GRAPEVINE, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Solo Brands, Inc. (NYSE: SBDS)(1) (“Solo Brands” or “the Company”) a leading portfolio of lifestyle brands (Solo Stove, Chubbies, Isle and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three and nine months ended September 30, 2025. “The third quarter was challenging, reflecting continued pressure on consumer demand while we rebuild retail relationships and work through excess retailer inventory primarily within our Solo Stove division.” said John Larson, President and Chief Executive Officer. “We maintained stable gross margins and generated...

VONORE, Tenn., Nov. 06, 2025 (GLOBE NEWSWIRE) — MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2026 first quarter ended September 28, 2025. The overview, commentary, and results provided herein relate to our continuing operations, which consists of our MasterCraft and Pontoon segments. Overview:Net sales for the first quarter were $69.0 million, up $3.6 million, or 5.6%, from the comparable prior-year period Income from continuing operations was $3.7 million, or $0.22 per diluted share, up from $1.0 million, or $0.06 per diluted share, in the prior-year period Adjusted Net Income, a non-GAAP measure, was $4.5 million, or $0.28 per diluted share, up from $1.9 million, or $0.12 per diluted share, in the prior-year period Adjusted EBITDA, a non-GAAP measure, was $6.7 million, up $2.9...